Gathers Diamone, Oswalt Cameron, Alder Laura, Chen Kevin, Higgins Jordyn P, Clarke Jeffrey M, Oduah Eziafa I
Duke University Health Systems, School of Medicine, Duke University, Durham, NC 27708, USA.
Duke Cancer Institute, Durham, NC 27710, USA.
Cancers (Basel). 2025 Jun 21;17(13):2077. doi: 10.3390/cancers17132077.
Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative immunotherapy in combination with chemotherapy. In this review, we explore the current treatment paradigms and emerging opportunities for improved survival outcomes from using immunotherapeutic approaches in the treatment of early-stage resectable NSCLC. The incorporation of immunotherapy into neoadjuvant, adjuvant, and perioperative treatment of surgically resectable NSCLC has yielded improved outcomes beyond chemotherapy-alone approaches. Despite this, there remains a margin for improving survival outcomes for patients. Clinical trials utilizing novel agents and approaches that modulate the anti-tumor immune response are currently ongoing and will likely inform the future treatment landscape for early-stage surgically resectable NSCLC.
从历史上看，可切除非小细胞肺癌（NSCLC）的全身治疗对总生存期的影响不大。早期可切除NSCLC的当前治疗选择包括新辅助、辅助和围手术期免疫疗法联合化疗。在本综述中，我们探讨了当前的治疗模式以及在早期可切除NSCLC治疗中使用免疫治疗方法改善生存结果的新机遇。将免疫疗法纳入可手术切除NSCLC的新辅助、辅助和围手术期治疗已产生了优于单纯化疗方法的结果。尽管如此，患者的生存结果仍有改善空间。目前正在进行利用新型药物和调节抗肿瘤免疫反应方法的临床试验，这些试验可能会为早期可手术切除NSCLC的未来治疗格局提供信息。
